Moderna Inc., US60770K1079

Moderna Inc. stock: EUR 180.50, down 1.85% premarket

Published on 11/19/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna develops mRNA-based medicines and vaccines, with oncology programs adding to its pipeline. On Xetra, the stock closed at EUR 183.90 on Wednesday, November 18, 2026.

Moderna's Premarket Direction

  • Moderna develops mRNA-based medicines and vaccines.
  • Management recently highlighted oncology development and further clinical milestones.
Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna Inc. stock traded at 180.50 euros on Lang & Schwarz at 07:50 CET on Thursday, November 19, 2026, 1.85 percent below the Xetra close of Wednesday, November 18, 2026, at 183.90 euros.

Moderna develops mRNA-based medicines and vaccines, while its oncology pipeline remains a central part of its growth strategy.

Broader market conditions can be followed through the S&P 500.

More news and analyses on Moderna Inc. stock

Disclaimer...
en | US60770K1079 | MODERNA INC. | boerse | 70534307 | bgmi